Five-Year Results from the IMPERIAL Randomized Study of Eluvia and Zilver PTX Drug-Eluting Stents and the Long Lesion Substudy for Femoropopliteal Artery Disease

Sunday, February 26, 2023

9:15 AM – 9:25 AM ET

Speaker(s)

William A. Gray, MD, FSCAI

System Chief of Cardiovascular Services, Main Line Health/President, Lankenau Heart Institute
Main Line Health
Wynnewood, Pennsylvania, United States

Disclosure(s): Alucent: Consultant (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Contracted Research (Ongoing); Edwards Lifesciences LLC: Consultant (Ongoing), Contracted Research (Ongoing); efemoral: Consultant (Ongoing); Medtronic: Consultant (Ongoing), Contracted Research (Ongoing); phillips: Consultant (Ongoing), Contracted Research (Ongoing); shockwave: Consultant (Ongoing), Contracted Research (Ongoing); W. L. Gore and Associates, Inc.: Consultant (Ongoing)

Disclosure(s):

William A. Gray, MD, FSCAI: Alucent: Consultant (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Contracted Research (Ongoing); Edwards Lifesciences LLC: Consultant (Ongoing), Contracted Research (Ongoing); efemoral: Consultant (Ongoing); Medtronic: Consultant (Ongoing), Contracted Research (Ongoing); phillips: Consultant (Ongoing), Contracted Research (Ongoing); shockwave: Consultant (Ongoing), Contracted Research (Ongoing); W. L. Gore and Associates, Inc.: Consultant (Ongoing)